Merus (MRUS) News Today

Merus (NASDAQ:MRUS - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for Merus in a research note issued on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings

Canaccord Genuity Group reiterated a "buy" rating and set a $67.00 price objective on shares of Merus in a research report on Thursday.

Susquehanna Fundamental Investments LLC acquired a new position in shares of Merus (NASDAQ:MRUS - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 39,910 shares of the biotechnology company's stock, valued at approximately $1,797,00

BNP Paribas Financial Markets lifted its stake in Merus (NASDAQ:MRUS - Free Report) by 63.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,885 shares of the biotechnology company's stock after buying an additio

Merus (NASDAQ:MRUS) Stock Price Up 5.2%

Merus (NASDAQ:MRUS - Get Free Report) COO Peter B. Silverman sold 10,000 shares of Merus stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Needham & Company LLC reiterated a "buy" rating and set a $92.00 price objective on shares of Merus in a research note on Friday.

Medicxi Ventures Management Jersey Ltd lessened its stake in Merus (NASDAQ:MRUS - Free Report) by 26.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,169,028 shares of the biotechnology company's stock after selli

Citigroup increased their price objective on shares of Merus from $70.00 to $93.00 and gave the stock a "buy" rating in a research report on Wednesday.

Bank of America reissued a "buy" rating and set a $76.00 price objective on shares of Merus in a report on Tuesday.

Wellington Management Group LLP trimmed its position in shares of Merus (NASDAQ:MRUS - Free Report) by 26.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,009,403 shares of the biotechnology company's stock after selli

Stifel Nicolaus upped their target price on shares of Merus from $90.00 to $99.00 and gave the company a "buy" rating in a report on Monday.

Parkman Healthcare Partners LLC increased its position in Merus (NASDAQ:MRUS - Free Report) by 20.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 157,817 shares of the biotechnology company's stock afte

Merus (NASDAQ:MRUS - Get Free Report) VP Harry Shuman sold 1,000 shares of the company's stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $53.22, for a total transaction of $53,220.00. Following the completion of the transaction, the vice president now directly owns 7,002 shares in the company, valued at approximately $372,646.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ADAR1 Capital Management LLC purchased a new position in shares of Merus (NASDAQ:MRUS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 24,000 shares of the biotechnology company's stock, valued at approximately

Merus (NASDAQ:MRUS) Trading 2.3% Higher

Bellevue Group AG reduced its holdings in Merus (NASDAQ:MRUS - Free Report) by 49.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,700 shares of the biotechnology company's stock after selling 21,800 sh

Avoro Capital Advisors LLC increased its holdings in shares of Merus (NASDAQ:MRUS - Free Report) by 100.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 888,888 shares of the biotechnology company's stock

RTW Investments LP raised its stake in Merus (NASDAQ:MRUS - Free Report) by 18.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,373,625 shares of the biotechnology company's stock after buying an additional 376,861 shares during the qu

Merus (NASDAQ:MRUS) Shares Down 2.2% on Analyst Downgrade

Canaccord Genuity Group boosted their price target on Merus from $54.00 to $67.00 and gave the company a "buy" rating in a report on Tuesday.

Campbell & CO Investment Adviser LLC acquired a new position in Merus (NASDAQ:MRUS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 48,007 shares of the biotechnology company's stock, v

Carmignac Gestion reduced its position in Merus (NASDAQ:MRUS - Free Report) by 11.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 403,861 shares of the biotechnology company's stock after selling 50,470 s

Merus (NASDAQ:MRUS) Trading Up 5.2%

Merus (NASDAQ:MRUS - Free Report) - Analysts at William Blair dropped their Q1 2025 EPS estimates for Merus in a research report issued to clients and investors on Tuesday, May 28th. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings per share of ($0.8

Trexquant Investment LP boosted its position in Merus (NASDAQ:MRUS - Free Report) by 138.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,489 shares of the biotechnology company's stock after buying a

Merus (NASDAQ:MRUS) Sees Large Volume Increase After Analyst Upgrade

Guggenheim upped their price target on Merus from $57.00 to $93.00 and gave the stock a "buy" rating in a research note on Tuesday.

BNP Paribas Financial Markets grew its position in Merus (NASDAQ:MRUS - Free Report) by 135.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,825 shares of the biotechnology company's stock after acq

Swiss National Bank decreased its stake in Merus (NASDAQ:MRUS - Free Report) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 72,654 shares of the biotechnology company's stock after selling 20,700 shares durin